Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

被引：17
|
作者：
Byrne, Michael [1 ]
Frattini, Mark G. [2 ]
Ottmann, Oliver G. [3 ]
Mantzaris, Ioannis [4 ]
Wermke, Martin [5 ]
Lee, Daniel J. [2 ]
Morillo, Daniel [6 ]
Scholz, Arne [7 ]
Ince, Stuart [8 ]
Valencia, Ray [7 ]
Souza, Fabricio [8 ]
Cordoba, Raul [6 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Dept Med, Hematol & Stem Cell Transplant Sect, Nashville, TN USA
[2] Columbia Univ, Med Ctr, New York, NY USA
[3] Cardiff Univ, Sch Med, Div Canc & Genet, Dept Haematol, Cardiff, S Glam, Wales
[4] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Hematol & Med Oncol, Bronx, NY 10467 USA
[5] Univ Canc Ctr Dresden, Dresden, Germany
[6] Hosp Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
[7] Bayer AG, Berlin, Germany
[8] Bayer HealthCare Pharmaceut, Whippany, NJ USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-117257
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4055
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY 1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical activity.
    Diamond, Jennifer Robinson
    Moreno, Victor
    Lim, Emerson A.
    Cordoba, Raul
    Cai, Charles
    Ince, Stuart James
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia
    Plunkett, W.
    Thomas, D. A.
    O'Brien, S. M.
    Federl, S.
    Giles, F. J.
    Nicol, S. J.
    Gill, J.
    Zhao, L.
    Ravandi, F.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] PHASE-I STUDY OF PYRAZOFURIN IN REFRACTORY ACUTE MYELOGENOUS LEUKEMIA
    VOGLER, WR
    TRULOCK, PD
    CANCER TREATMENT REPORTS, 1978, 62 (10): : 1569 - 1571
  • [4] Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia
    Attar, Eyal C.
    De Angelo, Daniel J.
    Supko, Jeffrey G.
    D'Amato, Ferdinando
    Zahrieh, David
    Sirulnik, Andres
    Wadleigh, Martha
    Ballen, Karen K.
    McAfee, Steve
    Miller, Kenneth B.
    Levine, James
    Galinsky, Ilene
    Trehu, Elizabeth G.
    Schenkein, David
    Neuberg, Donna
    Stone, Richard M.
    Amrein, Philip C.
    CLINICAL CANCER RESEARCH, 2008, 14 (05) : 1446 - 1454
  • [5] A Phase I Clinical Trial Using Eltrombopag in Patients with Acute Myelogenous Leukemia
    Frey, Noelle V.
    Hexner, Elizabeth O.
    Porter, David L.
    Mangan, James K.
    Loren, Alison W.
    Hatem, Joseph
    Bagg, Adam
    Perl, Alexander E.
    Tsai, Donald E.
    DiNardo, Courtney D.
    Heitjian, Daniel
    Luger, Selina M.
    Carroll, Martin
    BLOOD, 2012, 120 (21)
  • [6] Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia
    Liesveld, Jane L.
    O'Dwyer, Kristen
    Becker, Michael W.
    Mulford, Deborah
    Walker, Alison
    Chen, Rui
    Bechelli, Jeremy
    Rosell, Karen
    Jordan, Craig T.
    Minhajuddin, Mohammad
    Phillips, Gordon L., II
    BLOOD, 2012, 120 (21)
  • [7] A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)
    Murthy, Guru Subramanian Guru
    Kaufmann, Scott H.
    Szabo, Aniko
    Harrington, Alexandra M.
    Michaelis, Laura C.
    Abedin, Sameem
    Carlson, Karen
    Runaas, Lyndsey
    Longo, Walter L.
    Hinman, Alexander
    Maldonado-Schmidt, Sonia
    Thomas, Althea
    Baim, Arielle
    Litzow, Mark R.
    Atallah, Ehab L.
    BLOOD, 2021, 138
  • [8] Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops
    Luecking, Ulrich T.
    Scholz, Arne
    Kosemund, Dirk
    Bohlmann, Rolf
    Briem, Hans
    Lienau, Philip
    Siemeister, Gerhard
    Terebesi, Ildiko
    Meyer, Kirstin
    Prelle, Katja
    Valencia, Ray
    Ince, Stuart
    von Nussbaum, Franz
    Mumberg, Dominik
    Ziegelbauer, Karl
    Brands, Michael
    CANCER RESEARCH, 2017, 77
  • [9] A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia
    Perl, Alexander E.
    Kasner, Margaret T.
    Tsai, Donald E.
    Vogl, Dan T.
    Loren, Alison W.
    Schuster, Stephen J.
    Porter, David L.
    Stadtmauer, Edward A.
    Goldstein, Steven C.
    Frey, Noelle V.
    Nasta, Sunita D.
    Hexner, Elizabeth O.
    Dierov, Jamil K.
    Swider, Cezary R.
    Bagg, Adam
    Gewirtz, Alan M.
    Carroll, Martin
    Luger, Selina M.
    CLINICAL CANCER RESEARCH, 2009, 15 (21) : 6732 - 6739
  • [10] Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia
    Klimek, Virginia M.
    Dolezal, Emily K.
    Smith, Larry
    Soff, Gerald
    Nimer, Stephen D.
    LEUKEMIA RESEARCH, 2012, 36 (05) : 570 - 574
12345